Elevated urinary CCL2: Cr at 6 months is associated with renal allograft interstitial fibrosis and inflammation at 24 months

Transplantation

Volumn 98, Issue 1, 2014, Pages 39-46

  Ho, Julie ^a,b   Wiebe, Chris ^a   Gibson, Ian W ^a   Hombach Klonisch, Sabine ^a   Gao, Ang ^b   Rigatto, Claudio ^a   Karpinski, Martin ^a   Storsley, Leroy ^a   Nickerson, Peter W ^a,b   Rush, David N ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Chemokines; Chronic allograft injury; Monocyte chemoattractant protein 1; Urinary biomarker

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CREATININE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ADULT; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; GLOMERULOPATHY; GRAFT DYSFUNCTION; GRAFT FAILURE; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY HYPERTROPHY; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN URINE LEVEL; RENAL ALLOGRAFT INTERSTITIAL FIBROSIS; RENAL ALLOGRAFT INTERSTITIAL INFLAMMATION;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CANADA; CHEMOKINE CCL2; CHI-SQUARE DISTRIBUTION; CHRONIC DISEASE; CREATININE; FEMALE; FIBROSIS; HUMANS; KIDNEY TRANSPLANTATION; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEPHRITIS, INTERSTITIAL; ODDS RATIO; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UNITED STATES; UP-REGULATION;

EID: 84903793940     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000442776.40295.73     Document Type: Article

References (32)

1. Stegall MD, Park WD, Larson TS, et al. The histology of solitary renal allografts at 1 and 5 years after transplantation. Am J Transplant 2011; 11: 698.
2. OPTN/SRTR 2010 Annual Data Report. Dept. of Health & Human Services, Health Resources & Services Administration, Healthcare Systems Bureau, Division of Transplantation. Am J Transplant 2012; 12: 22.
3. Knoll G, Muirhead N, Trpeski L, et al. Patient survival following renal transplant failure in Canada. Am J Transplant 2005; 5: 1719.
4. Kaplan B, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. Am J Transplant 2002; 2: 970.
5. El-Zoghby ZM, Stegall MD, Lager DJ, et al. Identifying specific causes of kidney allograft loss. Am J Transplant 2009; 9: 527.
6. Wiebe C, Gibson IW, Blydt-Hansen TD, et al. Evolution and clinical pathologic correlations of de novo donor-specific HLA antibody post kidney transplant. Am J Transplant 2012; 12: 1157.
7. Matas AJ, Leduc R, Rush D, et al. Histopathologic clusters differentiate subgroups within the non-specific diagnoses of CAN or CR: preliminary data from the DeKAF study. Am J Transplant 2010; 10: 315.
8. Cosio FG, Grande JP, Wadei H, et al. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 2464.
9. Park WD, Griffin MD, Cornell LD, et al. Fibrosis with inflammation at one year predicts transplant functional decline. J Am Soc Nephrol 2010; 21: 1987.
10. Gago M, Cornell LD, Kremers WK, et al. Kidney allograft inflammation and fibrosis, causes and consequences. Am J Transplant 2012; 12: 1199.
11. Mannon RB, Matas AJ, Grande J, et al. Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure. Am J Transplant 2010; 10: 2066.
12. Shishido S, Asanuma H, Nakai H, et al. The impact of repeated subclinical acute rejection on the progression of chronic allograft nephropathy. J Am Soc Nephrol 2003; 14: 1046.
13. Mengel M, Reeve J, Bunnag S, et al. Scoring total inflammation is superior to the current Banff inflammation score in predicting outcome and the degree of molecular disturbance in renal allografts. Am J Transplant 2009; 9: 1859.
14. Moreso F, Ibernon M, Goma M, et al. Subclinical rejection associated with chronic allograft nephropathy in protocol biopsies as a risk factor for late graft loss. Am J Transplant 2006; 6: 747.
15. Kurtkoti J, Sakhuja V, Sud K, et al. The utility of 1- and 3-month protocol biopsies on renal allograft function: A randomized controlled study. Am J Transplant 2008; 8: 317.
16. Rush D, Nickerson P, Gough J, et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. J AmSocNephrol 1998; 9: 2129.
17. Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008; 8: 753.
18. Heilman RL, Devarapalli Y, Chakkera HA, et al. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563.
19. Rush D, Arlen D, Boucher A, et al. Lack of benefit of early protocol biopsies in renal transplant patients receiving TAC and MMF: a randomized study. Am J Transplant 2007; 7: 2538.
20. Ho J, Rush DN, Gibson IW, et al. Early urinary CCL2 is associated with the later development of interstitial fibrosis and tubular atrophy in renal allografts. Transplantation 2010; 90: 394.
21. Ho J, Wiebe C, Rush DN, et al. Increased urinary CCL2: Cr ratio at 6 months is associated with late renal allograft loss. Transplantation 2013; 95: 595.
22. Hu H, Kwun J, Aizenstein BD, et al. Noninvasive detection of acute and chronic injuries in human renal transplant by elevation of multiple cytokines/chemokines in urine. Transplantation 2009; 87: 1814.
23. Dubicksi B, Boratycska M, Kope (W, et al. Activated cells in urine and monocyte chemotactic peptide-1 (MCP-1)Vsensitive rejection markers in renal graft recipients. Transpl Immunol 2008; 18: 203.
24. Prodjosudjadi W, Daha MR, Gerritsma JS, et al. Increased urinary excretion of monocyte chemoattractant protein-1 during acute renal allograft rejection. Nephrol Dial Transplant 1996; 11: 1096.
25. Schaub S, Nickerson P, Rush D, et al. Urinary CXCL9 and CXCL10 levels correlate with the extent of subclinical tubulitis. Am J Transplant 2009; 9: 1347.
26. El Ters M, Grande JP, KeddisMT, et al. Kidney allograft survival after acute rejection, the value of follow-up biopsies. Am J Transplant 2013; 13: 2334.
27. Ho J, Rush DN, Karpinski M, et al. Validation of urinary CXCL10 as a marker of borderline, subclinical and clinical tubulitis. Transplantation 2011; 92: 878.
28. Hirt-Minkowski P, Amico P, Ho J, et al. Detection of clinical and subclinical tubulo-interstitial inflammation by the urinary CXCL10 chemokine in a real life setting. Am J Transplant 2012; 12: 1811.
29. Moreso F, Carrera M, Goma M, et al. Early subclinical rejection as a risk factor for late chronic humoural rejection. Transplantation 2012; 93: 41.
30. Hayde N, Bao Y, Pullman J, et al. The clinical and genomic significance of donor-specific antibody-positive/C4d-negative and donor-specific antibody-negative/C4d-negative transplant glomerulopathy. Clin J Am Soc Nephrol 2013; 8: 2141.
31. Amer H, Lieske JC, Rule AD, et al. Urine high and low molecular weight proteins one-year post-kidney transplant: relationship to histology and graft survival. Am J Transplant 2013; 13: 676.
32. Rush D, Somorjai R, Cecka M, et al. Urine magnetic resonance spectroscopy (UMRS): results from the Deterioration of Kidney Allograft Function (DeKAF) study. Am J Transplant 2009; 9: 350.